Abstract: The invention relates to wet skin treatment compositions having specific gum and acrylate dispersion stabilizer systems providing enhanced rheology (e.g., lotion-like rheology and spreadability) relative to other wet skin compositions.

Abstract: An anti-cancer composition having biocompatible materials, which can selectively exploit chemical variations between normal cells and cancer cells to inhibit or prevent the proliferation of cancerous cells and methods of use.

Abstract: An anti-cancer composition having biocompatible materials, which can selectively exploit chemical variations between normal cells and cancer cells to inhibit or prevent the proliferation of cancerous cells and methods of use.

Abstract: An anti-cancer composition having biocompatible materials, which can selectively exploit chemical variations between normal cells and cancer cells to inhibit or prevent the proliferation of cancerous cells and methods of use.

Abstract: An anti-cancer composition having biocompatible materials, which can selectively exploit chemical variations between normal cells and cancer cells to inhibit or prevent the proliferation of cancerous cells and methods of use.

Abstract: A convenient to use test method for comparing the relative affinity of surfactants for the skin employs a solid or semisolid matrix for associating a dye or pigment with the skin. The dye or pigment has an affinity to either the skin or a surfactant adsorbed on the skin during personal cleansing. The matrix may include a reagent soluble polymer film or temporary tattoo.

Abstract: The invention provides rinse-off wet skin compositions comprising structuring systems which in turn comprise (a) non-pre-gelatinized starch; and (b) fatty acid, and which systems provide enhanced properties. The fatty acid also needs to be added to the aqueous phase during preparation of the formulation.

Abstract: The invention relates to wet skin treatment compositions having specific gum and acrylate dispersion stabilizer systems providing enhanced rheology (e.g., lotion-like rheology and spreadability) relative to other wet skin compositions.

Abstract: This disclosure relates to a Composition having medicinal properties for use with mammalian diseases such as anti-cancer properties and methods of use, anti-viral properties and methods of use, anti-protozoan properties and methods of use, and anti-bacterial properties and methods of use in mammals. A chemical Composition for use as a pharmaceutical of a biologically acceptable copper compound and may include other components such as iron, which is transported to afflicted cells in a pharmaceutical acceptable carrier.

Abstract: An anti-cancer composition having biocompatible materials, which can selectively exploit chemical variations between normal cells and cancer cells to inhibit or prevent the proliferation of cancerous cells and methods of use.

Abstract: A garment is provided for aerodynamic assistance or propulsion of a rider-propelled wheeled vehicle comprising sail-like extensions extending from the abdominal portion of the garment and secured at a point between the hand and about the elbow of the rider while gripping the handle bars of the vehicle.

Abstract: A garment is provided for aerodynamic assistance or propulsion of a rider-propelled wheeled vehicle comprising sail-like extensions extending from the abdominal portion of the garment and secured at the hand of the rider while gripping the handle bars of the vehicle.

Abstract: A method is provided for increasing and maintaining the quantity and activity of immune leukocyte effector cells in preparation for lymphokine and cytokine administration before and during treatment for disease pathogens. The method simultaneously up-regulates the expression of high affinity IL-2 receptors on the above mentioned cells, making them receptive to subsequent IL-2 administration, which activates and directs these cells to mediate cytotoxic activity against disease pathogens. The method may also be employed in conjunction with the administration of other lymphokines, cytokines, biological response modifiers and pharmacological compounds whose activity would benefit from an increase in effector cells. The preferred method of administration is by inhalation of a zinc oxide fume or particulate from 15 to 900 mg ZnO/m.sup.3 for one or more exposures per day, one hour or less per exposure.

Abstract: A method is provided for treating multiple sclerosis by administering to a subject afflicted with that disease a symptom-alleviating amount of a compound selected from the group consisting of phytic acid, mixed counterion phytate salt, an isomer or hydrolysate of phytic acid or mixed counterion phytate salt, a mixture of any combination thereof, or with one or more dephosphorylating enzymes. The preferred method of administration is by oral dosages of about 1/2 to 3 grams/kilogram bodyweight per day.

Abstract: A method is provided for treating Parkinson's Disease by administering to a subject an effective symptom-alleviating amount of a compound selected from the group consisting of phytic acid, phytate salt, an isomer or hydrolysate of phytic acid or phytate salt, or a mixture of any combination thereof. The preferred method of administration is by oral dosages of about 1/8 to 1/2 grams/kilogram bodyweight per day.

Abstract: A method is provided for treating Parkinson's Disease by administering to a subject an effective symptom-alleviating amount of a compound selected from the group consisting of phytic acid, phytate salt, an isomer or hydrolysate of phytic acid or phytate salt, or a mixture of any combination thereof. The preferred method of administration is by oral dosages of about 1/8 to 1/2 grams/kilogram bodyweight per day.

Abstract: A method is provided for inhibiting tumor growth by administering to a subject an effective tumor-inhibiting amount of a compound selected from the group consisting of phytic acid, phytate salt, an isomer or hydrolysate of phytic acid or phytate salt, or a mixture of any combination thereof. The preferred method of administration is by oral dosages of about 2 to 4 grams/kilogram bodyweight per day.

Abstract: A method is provided for treating Alzheimer's Disease by administering to a subject an effective symptom-alleviating amount of a compound selected from the group consisting of phytic acid, phytate salt, an isomer or hydrolysate of phytic acid or phytate salt, or a mixture of any combination thereof. The preferred method of administration is by oral dosages of about 1/2 to 3 grams/kilogram bodyweight per day.

Abstract: A method is provided for treating Alzheimer's Disease by administering to a subject an effective symptom-alleviating amount of a compound selected from the group consisting of phytic acid, phytate salt, an isomer or hydrolysate of phytic acid or phytate salt, or a mixture of any combination thereof. The preferred method of administration is by oral dosages of about 1/2 to 3 grams/kilogram bodyweight per day.